FDA OKs urinary infection injectable drug

Oct 18, 2007

The U.S. Food and Drug Administration announced approval Thursday of doripenem (Doribax) injections for the treatment of complex urinary track infections.

The 500 mg intravenous infusion, also used to treat intra-abdominal infections, have been shown to be active against several strains of bacteria, the FDA said.

"This is a significant new drug in the treatment of hospitalized patients with serious bacterial infections," said Dr. Janet Woodcock, the FDA's deputy commissioner for scientific and medical programs.

Officials said doripenem, in several multi-center, multinational studies, was shown to have a cure rate comparable to the currently prescribed medications levofloxacin, used for complicated urinary tract infections, and meropenem, indicated for complicated intra-abdominal infections.

However, the FDA said the safety and effectiveness of doripenem injection in pediatric patients and pregnant women has not been established.

Doripenem injection is manufactured under the brand name Doribax by Johnson and Johnson Pharmaceutical Research and Development LLC of Raritan, N.J.

Copyright 2007 by United Press International

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

FDA OKs urinary infection injectable drug

Oct 18, 2007

The U.S. Food and Drug Administration announced approval Thursday of doripenem (Doribax) injections for the treatment of complex urinary tract infections.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0